Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins
Cencora Inc. (NYSE: COR ) on Wednesday reported third-quarter adjusted earnings of $4.48 per share, beating the consensus of $4.35. The pharmaceutical solutions organization reported sales of $84.754 billion, up 5.1% year-over-year, beating the consensus of $84.315 billion, driven by steady demand across its health car